Search results
For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medical breakthroughs to prevent, treat, and cure some of the world’s most vexing conditions and diseases. Learn more about our history.
At Pfizer, we have a long tradition of collaborating with external parties to advance medical breakthroughs. Discover our latest breakthroughs
Pfizer Inc. ( / ˈfaɪzər / FY-zər) [3] is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
Dec 11, 2020 · COMIRNATY is the first COVID-19 vaccine to be granted FDA approval. Approval is based on a comprehensive submission package including six-month efficacy and safety data after second dose. More than 1.2 billion Pfizer-BioNTech doses have been delivered to more than 120 countries or territories around the world since December 2020.
Pfizer Inc. and BioNTech SE today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains.
Highlighting progress in accelerating breakthrough cancer medicines at ASCO. Pfizer is showcasing new research across the company’s key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates and bispecific antibodies. Find Out More.
Nov 18, 2020 · This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program, and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical ...
Jun 25, 2022 · Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios for Omicron neutralizing antibody response ...
Oct 21, 2021 · First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain. In trial with more than 10,000 participants 16 years of age and older, COVID-19 booster was found to have a favorable safety profile.
